Attitudes Towards Deprescribing Medications in Cancer Patients and Impact of Educational Intervention by a Clinical Pharmacist
Launched by IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY · Jan 7, 2025
Trial Information
Current as of July 02, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how cancer patients in palliative care feel about reducing or stopping some of their non-cancer medications. It aims to understand patients' attitudes toward this process, known as deprescribing, and how information provided by a clinical pharmacist can help. If you participate, you'll answer some questions about your feelings towards your medications and understanding of your treatment. After that, you'll receive a brochure and watch a video that explains more about how medications work and the importance of being involved in your treatment decisions. At your next visit for cancer treatment, you'll be asked to answer some questions again.
To be eligible for this study, you should be a cancer patient receiving palliative care and have a performance status of 1 or 2, which means you can do some daily activities but may need assistance. If you're currently receiving treatment aimed at curing cancer or have significant cognitive difficulties, you will not be able to participate. This trial is not yet recruiting but is open to all patients aged 65 and older. Your insights could help improve how medications are managed for patients like you in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • cancer patients in palliative treatment
- • ECOG 1-2
- Exclusion Criteria:
- • cancer patients in curative treatment
- • ECOG 3-4
- • cognitive impairment
About Iuliu Hatieganu University Of Medicine And Pharmacy
Iuliu Hatieganu University of Medicine and Pharmacy is a prestigious academic institution located in Cluj-Napoca, Romania, renowned for its commitment to advancing medical education and research. As a clinical trial sponsor, the university leverages its extensive expertise in medical sciences and collaborative networks to facilitate innovative research initiatives aimed at improving healthcare outcomes. With a focus on ethical standards and regulatory compliance, the university fosters a dynamic environment for clinical investigations that contribute to the development of new therapies and enhance patient care. Its multidisciplinary approach and dedication to scientific excellence position it as a leading entity in the field of medical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baia Mare, Maramures, Romania
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported